Followers | 230 |
Posts | 15196 |
Boards Moderated | 0 |
Alias Born | 03/30/2005 |
Monday, October 05, 2020 6:42:14 AM
As a point of reference, my call with Leo a while back, as soon as I mentioned message board investment community, he quickly ended the call.
Some of you have picked up on my frustration with how the information is progressing and ipix's reticent stance. I have received supportive messages along with a few snarky comments.
There is more to the story that will come up in dribs and drabs to the public forum. My frustration is how the investment community is being handled here vs a select few. IPIX's PR's in August were very clear, yet anyone who questions the timeline is viewed as the enemy here or impatient.
The only thing that is clear, 60 days later the RBL is still nearing completion. The PRE-IND meeting request was granted to help the company file a subsequent IND " This pre-IND review will help result in a more efficient review of the subsequent IND
submission." - that comes straight out of the May FDA report. The completeness of the Pre-IND determines how fast we get to the IND. Let's hope "nearing completion" won't be part of IPIX's Q&A
I hope restraint will be shown. Let the company do it's thing. I am happy Leo decided to leave Q4 human trials out of his last PR, however the sales pitch was still provided "Given such interest in Brilacidin, the Company anticipates the planned COVID-19 trial can be rapidly recruited and completed."
Now that we are in front of the FDA, let's see what IPIX updates come out.
the above is all IMHO (consider this my safe harbor statement)
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM